BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26208475)

  • 1. Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients.
    Ananiev J; Aleksandrova E; Skerleva D; Gulubova M; Chokoeva A; Lotti T; Wollina U; Tchernev G; Kontić M; Stojšić J
    Wien Med Wochenschr; 2015 Aug; 165(15-16):315-21. PubMed ID: 26208475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer.
    Kuraoka K; Matsumura S; Hamai Y; Nakachi K; Imai K; Matsusaki K; Oue N; Ito R; Nakayama H; Yasui W
    Int J Cancer; 2003 Nov; 107(4):593-6. PubMed ID: 14520697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients.
    Satiroglu-Tufan NL; Bir F; Calli-Demirkan N
    World J Gastroenterol; 2006 May; 12(20):3283-7. PubMed ID: 16718853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
    Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
    Anticancer Res; 2015 Nov; 35(11):5901-4. PubMed ID: 26504013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma.
    Kruszyna Ł; Lianeri M; Roszak A; Jagodziński PP
    Clin Biochem; 2010 Apr; 43(6):545-8. PubMed ID: 20026098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.
    Lee SC; Hou MF; Hsieh PC; Wu SH; Hou LA; Ma H; Tsai SM; Tsai LY
    Clin Biochem; 2008 Feb; 41(3):121-5. PubMed ID: 18062925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
    Xie D; Shu XO; Deng Z; Wen WQ; Creek KE; Dai Q; Gao YT; Jin F; Zheng W
    J Natl Cancer Inst; 2000 Mar; 92(5):412-7. PubMed ID: 10699071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
    Siegfried JM; Lin Y; Diergaarde B; Lin HM; Dacic S; Pennathur A; Weissfeld JL; Romkes M; Nukui T; Stabile LP
    Neoplasia; 2015 Nov; 17(11):817-25. PubMed ID: 26678909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
    Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
    Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients.
    Kara N; Karakus N; Ulusoy AN; Ozaslan C; Gungor B; Bagci H
    DNA Cell Biol; 2010 Jul; 29(7):387-92. PubMed ID: 20380571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients.
    Sezgin E; Sahin FI; Yagmurdur MC; Demirhan B
    Genet Test Mol Biomarkers; 2011 Mar; 15(3):143-6. PubMed ID: 21204706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1.
    Kumagai T; Tomita Y; Nakatsuka SI; Kimura M; Kunimasa K; Inoue T; Tamiya M; Nishino K; Susaki Y; Kusu T; Tokunaga T; Okami J; Higashiyama M; Imamura F
    Thorac Cancer; 2018 Apr; 9(4):466-471. PubMed ID: 29473311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu Ile655Val polymorphism and the risk of breast cancer.
    Siddig A; Mohamed AO; Kamal H; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A
    Ann N Y Acad Sci; 2008 Sep; 1138():84-94. PubMed ID: 18837888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of HER2 genotypes as molecular markers on breast cancer outcome.
    Mutluhan H; Akbas E; Erdogan NE; Soylemez F; Senli MS; Polat A; Helvaci I; Seyrek E
    DNA Cell Biol; 2008 Oct; 27(10):575-9. PubMed ID: 18721072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study on the expression of CASP9 gene and its polymorphism distribution in non-small cell lung cancer].
    Lou Y; Fang CQ; Li JH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):59-62. PubMed ID: 17285546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
    Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.
    Nguyen Thanh T; Nguyen Tran BS; Hoang Thi AP; Tran Binh T; Ba Nguyen T; Le Minh T; Nguyen Vu QH; Dang Cong T
    Asian Pac J Cancer Prev; 2021 Jan; 22(1):11-18. PubMed ID: 33507673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
    Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
    APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.